EC Neurology

Review Article Volume 16 Issue 2 - 2024

The Essentials in Corticobasal Degeneration

Sacristán HE1*, Cvitanich FR2, Mentana N2 and Liotta CA3

1Department of Neurology, Director of Teaching and Research Committee “Dr. Anselmo Marini” Municipal Rehabilitation Institute, Vicente Lopez, Buenos Aires and Professor of Neurology, School of Medicine, University of Morón and Professor of Neurology, School of Medicine, UBA, Argentina
2Hospital Teaching Unit, Prof. Bernardo Houssay Hospital, School of Medicine, UBA, Argentina
3ABFM - Shoals Primary Care, Sheffield, Alabama, USA

*Corresponding Author: Sacristán HE, Department of Neurology, Director of Teaching and Research Committee “Dr. Anselmo Marini” Municipal Rehabilitation Institute, Vicente Lopez, Buenos Aires and Professor of Neurology, School of Medicine, University of Morón and Professor of Neurology, School of Medicine, UBA, Argentina.
Received: January 26, 2024; Published: February 07, 2024



Diseases that affect the basal nuclei are characterized by slowness and a reduction in the range of movement (bradykinesia-hypokinesia), often associated with tremor, rigidity, and postural alterations. The term 'parkinsonisms' refers to these findings, the most common etiology of which is Parkinson's disease (PD). There are akineto-rigid parkinsonisms, especially without tremor, that do not respond to L-dopa and correspond to one of these three neurodegenerative disorders: 1) progressive supranuclear palsy (PSP), 2) multiple system atrophy (MSA), or 3) corticobasal degeneration (CBD). Each of them has characteristic signs and symptoms that distinguish them from PD, but these may not be present at the beginning of the disease. These conditions usually do not respond to dopaminergic drugs and must be addressed correctly in the early phase. The main problem is that patients with typical clinical signs and symptoms of PD can have very diverse pathologies, and patients with the same pathology can have different clinical signs and symptoms (atypical parkinsonisms with typical or atypical presentation). Recently, interest has grown in the knowledge of these diseases, characterized by abnormal intracellular accumulation of misfolded proteins, such as tau (PSP and CBD) and α-synuclein (MSA). Knowledge of the characteristic signs and symptoms of PSP, MSA, and CBD is essential for the adequate diagnostic and therapeutic management of patients suffering from atypical parkinsonisms. CBD is a rare entity. In the present work, we will develop the clinical characteristics and various treatment options in clinical practice.

 Keywords: Parkinsonisms; Corticobasal Degeneration; Diagnosis; Treatment

 

  1. Robert K Mahapatra., et al. “Corticobasal degeneration”. The Lancet Neurology12 (2004): 736-743.
  2. Pantelyat Alexander. “Progressive supranuclear palsy and corticobasal syndrome”. American Academy of Neurology (2022).
  3. Olanow Warren., et al. “Parkinson´s disease and other movement disorders”. Chapter 36. Harrisons Neurology in Clinical Medicine (2017): 408-434.
  4. Rebeiz JJ., et al. “Corticodentatonigral degeneration with neuronal achromasia”. Archives of Neurology 1 (1968): 20-33.
  5. Gibb WRG., et al. “Corticobasal degeneration”. Brain5 (1989): 1171-1192.
  6. Saranza GM., et al. “Corticobasal degeneration”. International Review of Neurobiology 149 (2019): 87-136.
  7. Kouri N., et al. “Corticobasal degeneration: a pathologically distinct 4R tauopathy”. Nature Reviews Neurology 5 (2011): 263-272.
  8. Stamelou M., et al. ““Atypical parkinsonism”: New genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy-A diagnostic guide”. Movement Disorders9 (2013): 1184-1199.
  9. Amstrong MJ and Lang Anthony. “Corticobasal degeneration and corticobasal syndrome”. Wolters and Baumann, “Parkinson Disease and Other Movement Disorders”. Chapter 21 (2014): 411-421.
  10. Vasilios C Constantinides., et al. “Corticobasal degeneration and corticobasal syndrome: A review”. Clinical Parkinsonism and Related Disorders 1 (2019): 66-71.
  11. Suzee E Lee., et al. “Clinico pathological correlations in corticobasal degeneration”. Annals of Neurology 2 (2011): 327-340.
  12. Armstrong MJ., et al. “Criteria for the diagnosis of corticobasal degeneration”. Neurology5 (2013): 496-503.
  13. Johannes Levin., et al. “The differential diagnosis and treatment of atypical parkinsonism”. Deutsches Ärzteblatt International5 (2016): 61-69.
  14. Sacristán HE and Serra Fulles JA. “Enfermedad de Parkinson. Consideraciones clínicas”. Revista de Medicina Interna de Buenos Aires 4 (2022): 149-160.
  15. Anastassia M Mena and Antonio P Strafella. “Imaging pathological tau in atypical parkinsonisms: A review”. Clinical Parkinsonism and Related Disorders 7 (2022): 100155.
  16. Saeed U., et al. “Neuroimaging advances in Parkinson’s disease and atypical parkinsonian syndromes”. Frontiers in Neurology 11 (2020): 572976.
  17. Walker Z., et al. “Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia”. European Journal of Nuclear Medicine and Molecular Imaging9 (2018): 1534-1545.
  18. Vaquer-Alice J., et al. “Tau strains shape disease”. Acta Neuropathological1 (2021): 57-71.
  19. Wilson D., et al. “Corticobasal syndrome: a practical guide”. Practical Neurology4 (2021): 276-285.
  20. Bluett B., et al. “Best practices in the clinical management of progressive supranuclear palsy and corticobasal syndrome: A consensus statement of the cure PSP centers of care”. Frontiers in Neurology 12 (2021): 694872.
  21. Dickson DW., et al. “Office of rare diseases neuropathological criteria for corticobasal degeneration”. Journal of Neuropathology and Experimental Neurology 11 (2002): 935-946.
  22. Amstrong MJ., et al. “Criteria for the diagnosis of corticobasal degeneration”. Neurology5 (2013): 496-503.
  23. Lang AE., et al. “The cortical basal ganglia functional scale (CBFS): Development and preliminary validation”. Parkinsonism and Related Disorders 79 (2020): 121-126.
  24. Murray R., et al. “Cognitive and motor assessment in autopsy proven corticobasal degeneration”. Neurology 16 (2007): 1274-1283.
  25. Wenning GK., et al. “Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination”. Journal of Neurology, Neurosurgery and Psychiatry 2 (1998): 184-189.
  26. Josephs KA., et al. “Rapidly progressive neurodegenerative dementias”. Archives of Neurology 2 (2009): 201-207.
  27. Lee W., et al. “Characterizing the uncommon corticobasal syndrome presentation of sporadic Creutzfeldt-Jakob disease”. Parkinsonism and Related Disorders 1 (2013): 81-85.
  28. Vanek Z and Jankovic J. “Dystonia in corticobasal degeneration”. Movement Disorders2 (2001): 252-257.
  29. Kompoliti K., et al. “Clinical presentation and pharmacologic therapy in corticobasal degeneration”. Archives of Neurology7 (1998): 957-961.
  30. Frucht S., et al. “L-dopa induced dyskinesias in autopsy-proven cortical basal ganglionic degeneration”. Movement Disorders 2 (2000): 340-343.
  31. Nicolaus R Mc Farland. “Diagnostic approach to atypical parkinsonian syndromes”. Continuum4 (2016): 1117-1142.

Sacristán HE., et al. “The Essentials in Corticobasal Degeneration”. EC Neurology  16.2 (2024): 01-14.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net